In the December 2016 issue, the piece “Drugs that made headlines in 2016” (Nat. Med. 22, 1377–1379, 2016) incorrectly stated that the FDA was further reviewing the drug Keytruda for a common form of lung cancer under priority review. The approval that had been given to the drug in October was the result of a priority review. The error has been corrected in the HTML and PDF versions of this article.
Additional information
The online version of the original article can be found at 10.1038/nm1216-1377
Rights and permissions
About this article
Cite this article
Correction. Nat Med 23, 140 (2017). https://doi.org/10.1038/nm0217-140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0217-140
